{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 448137147
| IUPAC_name = (2-Hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
| image = Trimazosin.svg
| width = 275

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 53746-46-6
| ATC_prefix = C02
| ATC_suffix = CA03
| PubChem = 37264
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 31L760807H
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 513301
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 34203
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D08212
| smiles = O=C(OCC(O)(C)C)N3CCN(c1nc(N)c2c(n1)c(OC)c(OC)c(OC)c2)CC3
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = YNZXWQJZEDLQEG-UHFFFAOYSA-N

<!--Chemical data-->
| C=20 | H=29 | N=5 | O=6 
| molecular_weight = 435.47 g/mol
}}

'''Trimazosin''' is a [[sympatholytic]] [[alpha blocker]].<ref name="pmid3780829">{{cite journal |vauthors=van Kalken CK, van der Meulen J, Oe PL, Vriesendorp R, Donker AJ |title=Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension |journal=Eur. J. Clin. Pharmacol. |volume=31 |issue=1 |pages=63â€“8 |year=1986 |pmid=3780829 |doi= 10.1007/BF00870988|url=}}</ref><ref>{{US Patent|3,669,968}}</ref>

==References==
{{reflist}}

{{Adrenergics}}
{{Antihypertensives and diuretics}}
{{Piperazines}}

[[Category:Carbamates]]
[[Category:Phenol ethers]]
[[Category:Piperazines]]
[[Category:Quinazolines]]

{{antihypertensive-stub}}